ESTRELLA IMMUNOPHARMA INC (ESLA) Fundamental Analysis & Valuation

NASDAQ:ESLA • US2975841048

Current stock price

1.88 USD
+0.22 (+13.25%)
Last:

This ESLA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ESLA Profitability Analysis

1.1 Basic Checks

  • ESLA had negative earnings in the past year.
  • In the past year ESLA has reported a negative cash flow from operations.
  • In the past 5 years ESLA always reported negative net income.
  • ESLA had a negative operating cash flow in each of the past 5 years.
ESLA Yearly Net Income VS EBIT VS OCF VS FCFESLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -5M -10M -15M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -411.19%, ESLA is doing worse than 93.60% of the companies in the same industry.
Industry RankSector Rank
ROA -411.19%
ROE N/A
ROIC N/A
ROA(3y)-314.12%
ROA(5y)-195.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ESLA Yearly ROA, ROE, ROICESLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 100 -100 -200 -300 -400

1.3 Margins

  • ESLA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ESLA Yearly Profit, Operating, Gross MarginsESLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. ESLA Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, ESLA has more shares outstanding
  • There is no outstanding debt for ESLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ESLA Yearly Shares OutstandingESLA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2025 10M 20M 30M
ESLA Yearly Total Debt VS Total AssetsESLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2025 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -31.21, we must say that ESLA is in the distress zone and has some risk of bankruptcy.
  • ESLA has a Altman-Z score of -31.21. This is amonst the worse of the industry: ESLA underperforms 88.76% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -31.21
ROIC/WACCN/A
WACCN/A
ESLA Yearly LT Debt VS Equity VS FCFESLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 2025 0 20M 40M

2.3 Liquidity

  • A Current Ratio of 0.12 indicates that ESLA may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.12, ESLA is doing worse than 94.38% of the companies in the same industry.
  • A Quick Ratio of 0.12 indicates that ESLA may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.12, ESLA is doing worse than 94.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.12
Quick Ratio 0.12
ESLA Yearly Current Assets VS Current LiabilitesESLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ESLA Growth Analysis

3.1 Past

  • ESLA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -50.23%.
EPS 1Y (TTM)-50.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ESLA will show a very strong growth in Earnings Per Share. The EPS will grow by 56.73% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y15.22%
EPS Next 2Y14.21%
EPS Next 3Y14.47%
EPS Next 5Y56.73%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ESLA Yearly Revenue VS EstimatesESLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
ESLA Yearly EPS VS EstimatesESLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

0

4. ESLA Valuation Analysis

4.1 Price/Earnings Ratio

  • ESLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ESLA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ESLA Price Earnings VS Forward Price EarningsESLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ESLA Per share dataESLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.1 -0.2 -0.3

4.3 Compensation for Growth

  • ESLA's earnings are expected to grow with 14.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.21%
EPS Next 3Y14.47%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ESLA Dividend Analysis

5.1 Amount

  • ESLA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ESLA Fundamentals: All Metrics, Ratios and Statistics

ESTRELLA IMMUNOPHARMA INC

NASDAQ:ESLA (4/17/2026, 8:08:44 PM)

1.88

+0.22 (+13.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-18
Earnings (Next)N/A
Inst Owners2.46%
Inst Owner Change0%
Ins Owners1.88%
Ins Owner Change0%
Market Cap80.22M
Revenue(TTM)N/A
Net Income(TTM)-13.06M
Analysts82.86
Price Target8.16 (334.04%)
Short Float %3.78%
Short Ratio2.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.42%
Min EPS beat(2)-33.69%
Max EPS beat(2)46.52%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-50%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)36.07%
EPS NY rev (3m)45.83%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.36
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0
BVpS-0.24
TBVpS-0.24
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -411.19%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-314.12%
ROA(5y)-195.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.12
Quick Ratio 0.12
Altman-Z -31.21
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
EPS Next Y15.22%
EPS Next 2Y14.21%
EPS Next 3Y14.47%
EPS Next 5Y56.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-47.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y88.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y88.89%
OCF growth 3YN/A
OCF growth 5YN/A

ESTRELLA IMMUNOPHARMA INC / ESLA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ESTRELLA IMMUNOPHARMA INC (ESLA) stock?

ChartMill assigns a fundamental rating of 0 / 10 to ESLA.


Can you provide the valuation status for ESTRELLA IMMUNOPHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to ESTRELLA IMMUNOPHARMA INC (ESLA). This can be considered as Overvalued.


Can you provide the profitability details for ESTRELLA IMMUNOPHARMA INC?

ESTRELLA IMMUNOPHARMA INC (ESLA) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ESTRELLA IMMUNOPHARMA INC?

The Earnings per Share (EPS) of ESTRELLA IMMUNOPHARMA INC (ESLA) is expected to grow by 15.22% in the next year.